Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients - Aix-Marseille Université Access content directly
Journal Articles World journal of hepatology Year : 2018

Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients

Dominique Salmon
  • Function : Author
Pascale Trimoulet
  • Function : Author
Camille Gilbert
  • Function : Author
Caroline Solas
Eva Lafourcade
  • Function : Author
Julie Chas
  • Function : Author
Lionel Piroth
  • Function : Author
Karine Lacombe
Christine Katlama
  • Function : Author
Gilles Peytavin
  • Function : Author
Hugues Aumaitre
  • Function : Author
Laurent Alric
  • Function : Author
  • PersonId : 881462
Francois Boue
  • Function : Author
Philippe Morlat
  • Function : Author
Eric Billaud
  • Function : Author
Eric Rosenthal
  • Function : Author
Alissa Naqvi
  • Function : Author
Patrick Miailhes
  • Function : Author
Firouze Bani-Sadr
  • Function : Author
Laure Esterle
Francois Dabis
  • Function : Author
Philippe Sogni
  • Function : Author
Linda Wittkop

Abstract

AIM To describe factors associated with treatment failure and frequency of resistance-associated substitutions (RAS). METHODS Human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfected patients starting a first direct-acting antiviral (DAA) regimen before February 2016 and included in the French ANRS CO13 HEPAVIH cohort were eligible. Failure was defined as: (1) non-response [HCV-RNA remained detectable during treatment, at end of treatment (EOT)]; and (2) relapse (HCV-RNA suppressed at EOT but detectable thereafter). Sequencing analysis was performed to describe prevalence of drug class-specific RAS. Factors associated with failure were determined using logistic regression models. RESULTS Among 559 patients, 77% had suppressed plasma HIV-RNA < 50 copies/mL at DAA treatment initiation, 41% were cirrhotic, and 68% were HCV treatment-experienced. Virological treatment failures occurred in 22 patients and were mainly relapses (17, 77%) then undefined failures (3, 14%) and non-responses (2, 9%). Mean treatment duration was 16 wk overall. Post-treatment NS3, NS5A or NS5B RAS were detected in 10/14 patients with samples available for sequencing analysis. After adjustment for age, sex, ribavirin use, HCV genotype and treatment duration, low platelet count was the only factor significantly associated with a higher risk of failure (OR: 6.5; 95%CI: 1.8-22.6). CONCLUSION Only 3.9% HIV-HCV coinfected patients failed DAA regimens and RAS were found in 70% of those failing. Low platelet count was independently associated with virological failure.

Dates and versions

hal-02146873 , version 1 (04-06-2019)

Identifiers

Cite

Dominique Salmon, Pascale Trimoulet, Camille Gilbert, Caroline Solas, Eva Lafourcade, et al.. Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients. World journal of hepatology, 2018, 10 (11), pp.856-866. ⟨10.4254/wjh.v10.i11.856⟩. ⟨hal-02146873⟩
78 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More